Myocardial infarction

From Wikipedia, the free encyclopedia

Myocardial infarction
Classifications and external resources
Diagram of a myocardial infarction (2) of the tip of the anterior wall of the heart (an apical infarct) after occlusion (1) of a branch of the left coronary artery (LAC, right coronary artery = RAC).
ICD-10 I21.-I22.
ICD-9 410
DiseasesDB 8664
MedlinePlus 000195
eMedicine med/1567  emerg/327 ped/2520

Acute myocardial infarction (AMI or MI), commonly known as a heart attack, is a disease that occurs when the blood supply to a part of the heart is interrupted. The resulting oxygen shortage causes damage and potential death of heart tissue. It is a medical emergency, and the leading cause of death for both men and women all over the world.[1] Important risk factors are older age, smoking, high LDL ("bad cholesterol") and low HDL ("good cholesterol"), diabetes, high blood pressure, and obesity.

The term myocardial infarction is derived from myocardium (the heart muscle) and infarction (tissue death due to oxygen starvation). The phrase "heart attack" sometimes refers to heart problems other than MI, such as unstable angina pectoris and sudden cardiac death.

Myocardial infarctions are usually accompanied by characteristic severe chest pain and autonomic phenomena such as looking pale, sweating and feeling sick.

Initial treatment measures for someone suspected of suffering from an acute myocardial infarction include oxygen, aspirin, glyceryl trinitrate and pain relief. While these are being administered, diagnostic tests are often performed, including serial electrocardiograms (ECG, EKG), X-rays and blood tests. Further treatment may include either medications to break down blood clots that block the blood flow to the heart, or mechanically restoring the flow by dilatation or bypass surgery of the blocked coronary artery. Coronary care unit admission allows rapid and safe treatment of complications such as abnormal heart rhythms.

Contents

[edit] Epidemiology

Myocardial infarction is a common presentation of ischemic heart disease. The WHO estimated that in 2002, 12.6% of deaths worldwide were from ischemic heart disease.[1] Ischemic heart disease is the leading cause of death in developed countries, but third to AIDS and lower respiratory infections in developing countries.[2]

In the United States, diseases of the heart are the leading cause of death, causing a higher mortality than cancer (malignant neoplasms).[3] Coronary heart disease is responsible for 1 in every 5 deaths in the U.S.. Some 7,200,000 men and 6,000,000 women are living with some form of coronary heart disease. 1,200,000 people suffer a (new or recurrent) coronary attack every year, and about 40% of them die as a result of the attack.[4] This roughly means that every 65 seconds, an American dies of a coronary event.[5]

[edit] Risk factors

Risk factors for atherosclerosis may also be risk factors for coronary artery disease:[6]

These major factors are most often modifiable, so heart attacks can generally be prevented by a healthier lifestyle. Physical activity is associated with a lower risk profile.[8] Non-modifiable factors besides age and gender include a family history of an early heart attack (before the age of 60), which is thought of as reflecting a genetic predisposition.[6]

Socioeconomic factors such as a shorter education and lower income (particularly in women), as well as living with a partner attribute to the risk of MI.[9] To understand epidemiological study results, it's important to note that many factors associated with MI mediate their risk via other factors. For example, the effect of education is partially based on its effect on income and marital status.[9]

Women who use oral contraceptives have a modestly increased risk of myocardial infarction, especially if they also have other risk factors, such as smoking.[10]

Inflammation is known to be an important step in the process of atherosclerotic plaque formation. C-reactive protein (CRP) is a sensitive but non-specific marker for inflammation. Elevated CRP blood levels, especially measured with high sensitivity assays, can predict the risk of MI, as well as stroke and development of diabetes. Moreover, some drugs for MI might also reduce CRP levels.[11] The use of high sensitivity CRP assays as a means of screening the general population is advised against, but it may be used optionally at the physician's discretion, in patients who already present with other risk factors or known coronary artery disease.[12] Whether CRP plays a direct role in atherosclerosis remains uncertain.[11]

Inflammation in periodontal disease could play a role in coronary heart disease, and since periodontitis is very common, this could have great consequences for public health.[13] Serological studies measuring antibody levels against typical periodontitis-causing bacteria found that such antibodies were more present in subjects with coronary heart disease.[14] Periodontitis tends to increase blood levels of CRP, fibrinogen and cytokines;[15] thus, periodontitis may mediate its effect on MI risk via other risk factors.[16] Preclinical research suggests that periodontal bacteria can promote aggregation of platelets and promote the formation of foam cells.[17][18] A role for specific periodontal bacteria has been suggested but remains to be established.[19]

Baldness, hair greying, a diagonal earlobe crease[20] and possibly other skin features are independent risk factors for MI. Their role remains controversial; a common denominator of these signs and the risk of MI is supposed, possibly genetic.[21]

[edit] Pathophysiology

A myocardial infarction occurs when an atherosclerotic plaque slowly builds up in the inner lining of a coronary artery and then suddenly ruptures, totally occluding the artery and preventing blood flow downstream.
Enlarge
A myocardial infarction occurs when an atherosclerotic plaque slowly builds up in the inner lining of a coronary artery and then suddenly ruptures, totally occluding the artery and preventing blood flow downstream.

The term "myocardial infarction" literally means that there is destruction of heart muscle cells due to a lack of oxygen. If these cells are not supplied with sufficient oxygen by the coronary arteries to meet their metabolic demands, they die by a process called infarction. Not all "heart attacks" lead to loss of heart muscle, particularly if the heart attack is aborted.

The decrease in blood supply has several consequences. Heart muscle which has lost blood flow long enough, for example 10–15 minutes, undergoes the ischemic cascade; the cells die (chiefly through necrosis) and do not grow back. A collagen scar, which does not have the ability to contract, forms in its place. Thus the heart ends up permanently weaker as a pump for the remainder of the individual's life. Recent studies indicate that another form a cell death called apoptosis also plays a role in the process of tissue damage subsequent to myocardial infarction.[22]

Injured, but still living, heart muscle conducts the electrical impulses which initiate each heart beat much more slowly. The speed can become so slow that the spreading impulse is preserved long enough for the uninjured muscle to complete contraction. Under certain conditions, the slowed electrical signal, still travelling within the injured area, can re-enter and trigger the healthy muscle to beat again too soon. Rapid rythm abnormalities can occur, such as atrial fibrillation. These may again reduce the filling of the heart, and thus negatively influence the function of the heart. If this re-entry process results in sustained heart rates in the 200 to over 400 beats per minute range, a phenomenon called ventricular tachycardia (V-Tach) or ventricular fibrillation (V-Fib), then the rapid heart rate prevents the heart from pumping blood effectively. Heart output and blood pressure falls to near zero and the individual quickly dies. This is the most common mechanism of the sudden death that can result from a myocardial infarction.

The cardiac defibrillator device was specifically designed for stopping these too rapid heart rates. If used properly, it stops and resets the electrical impulses in all heart cells —in effect "rebooting" the heart. It stimulates the entire heart muscle to contract together in synchrony, hopefully stopping continuation of the re-entry process. If used within one minute of onset of V-Tach or V-Fib, the defibrillator has a high success rate in stopping these often fatal arrhythmias allowing a functional heart rhythm to return.[citation needed]

[edit] Causes

The most common cause of heart attack by far is atherosclerosis, a gradual buildup of cholesterol and fibrous tissue in plaques in the wall of arteries (in this case, the coronary arteries), typically over decades. Blood stream column irregularities visible on angiographies reflect artery lumen narrowing as a result of decades of advancing atherosclerosis. Plaques can become unstable, rupture, and additionally promote a thrombus (blood clot) that occludes the artery; this can occur in minutes. When a severe enough plaque rupture occurs in the coronary vasculature, it leads to myocardial infarction (necrosis of downstream myocardium).

Heart attacks rates are higher in association with intense exertion, be it psychological stress or physical exertion, especially if the exertion is more intense than the individual usually performs. Quantitatively, the period of intense exercise and subsequent recovery is associated with about a 6-fold higher myocardial infarction rate (compared with other more relaxed times frames) for people who are physically very fit. For those in poor physical condition, the rate differential is over 35-fold higher. One observed mechanism for this phenomenon is the increased arterial pulse pressure stretching and relaxation of arteries with each heart beat which, as has been observed with intravascular ultrasound, increases mechanical "shear stress" on atheromas and the likelihood of plaque rupture.

Increased spasm/contraction of coronary arteries and left ventricular hypertrophy in association with cocaine abuse can also precipitate myocardial infarction.

Acute severe infection, such as pneumonia, can trigger myocardial infarction. A more controversial link is that between Chlamydophila pneumoniae infection and atherosclerosis. While this intracellular organism has been demonstrated in atherosclerotic plaques, evidence is inconclusive as to whether it can be considered a causative factor. Treatment with antibiotics in patients with proven atherosclerosis has not demonstrated a decreased risk of heart attacks or other coronary vascular diseases.

[edit] Classification

According to the ICD-10's chapter on cardiovascular disease, myocardial infarction is a form of ischemic heart disease. The latter comprises several forms of angina pectoris, acute myocardial infarction (AMI), subsequent myocardial infarction, certain complications, other acute ischemic heart diseases (such as the postmyocardial infarction syndrome), and chronic ischemic heart disease (which includes, for example, coronary atherosclerosis, old MI, ischemic cardiomyopathy and silent myocardial ischemia).[23] The term coronary heart disease refers to heart diseases that originate from atherosclerosis of the coronary arteries. Many people have this condition without symptoms, but as it progresses it can cause myocardial infarction or angina pectoris.

Electrocardiography (ECG) allows to distinguish between different subtypes of myocardial infarction (ST-elevation myocardial infarction, STEMI and non-ST-elevation myocardial infarction, NSTEMI, discussed below).

Depending on the location of the obstruction in the coronary circulation, different zones of the heart can become injured. Using the anatomical terms of location, one can describe anterior, inferior, lateral, apical and septal infarctions (and combinations, such as anteroinferior, anterolateral, and so on).[24] For example, an occlusion of the left anterior descending coronary artery will result in an anterior wall myocardial infarct.[25]

Another distinction is whether a MI is subendocardial, affecting only the inner third to one half of the heart muscle, or transmural, damaging (almost) the entire wall of the heart.[26] The inner part of the heart muscle is more vulnerable to oxygen shortage, because the coronary arteries run inward from the epicardium to the endocardium, and because the blood flow through the heart muscle is hindered by the heart contraction.[25]

The phrases transmural and subendocardial infarction used to be considered synonymous with Q-wave and non-Q-wave myocardial infarction respectively, based on the presence or absence of Q waves on the ECG. It has since been shown that there is no clear correlation between the presence of Q waves with a transmural infarction and the absence of Q waves with a subendocardial infarction,[27] but Q waves are associated with larger infarctions, while the lack of Q waves is associated with smaller infarctions. The presence or abscence of Q-waves also has clinical importance,[28] with improved outcomes associated with a lack of Q waves.[29]

[edit] Symptoms

Rough diagram of pain zones in myocardial infarction (dark red = most typical area, light red = other possible areas, view of the chest).
Enlarge
Rough diagram of pain zones in myocardial infarction (dark red = most typical area, light red = other possible areas, view of the chest).
Back view.
Enlarge
Back view.

The onset of symptoms in myocardial infarction (MI) is usually gradual, over several minutes, and rarely instantaneous.[30] Chest pain is the most common symptom of acute myocardial infarction and is often described as a sensation of tightness, pressure, or squeezing. Chest pain due to ischemia (a lack of blood and hence oxygen supply) of the heart muscle is termed angina pectoris. Pain radiates most often to the left arm, but may also radiate to the lower jaw, neck, right arm, back, and epigastrium, where it may mimic heartburn. Any group of symptoms compatible with a sudden interruption of the blood flow to the heart are called an acute coronary syndrome.[31]

Shortness of breath (dyspnea) occurs when the damage to the heart limits the output of the left ventricle, causing left ventricular failure and consequent pulmonary edema. Other symptoms include diaphoresis (an excessive form of sweating), weakness, light-headedness, nausea, vomiting, and palpitations. Loss of consciousness and even sudden death can occur in myocardial infarctions and are poor prognostic indicators.

Women often experience different symptoms than men. The most common symptoms of MI in women include dyspnea, weakness, and fatigue. Fatigue, sleep disturbances, and dyspnea have been reported as frequently occurring symptoms which may manifest as long as one month before the actual clinically manifested ischemic event. In women, chest pain may be less predictive of coronary ischemia than in men.[32]

Approximately half of all MI patients have experienced warning symptoms such as chest pain prior to the infarction.[33]

Approximately one third of all myocardial infarctions are silent, without chest pain or other symptoms.[34] These cases can be discovered later on electrocardiograms or at autopsy without a prior history of related complaints. A silent course is more common in the elderly, in patients with diabetes mellitus[35] and after heart transplantation, probably because the donor heart is not connected to nerves of the host.[36] In diabetics, differences in pain threshold, autonomic neuropathy, and psychological factors have been cited as possible explanations for the lack of symptoms.[35]

[edit] Diagnosis

The diagnosis of myocardial infarction is made by integrating the history of the presenting illness and physical examination with electrocardiogram findings and cardiac markers (blood tests for heart muscle cell damage).[37] A coronary angiogram allows to visualize narrowings or obstructions on the heart vessels, and therapeutic measures can follow immediately. At autopsy, a pathologist can diagnose a myocardial infarction based on anatomopathological findings.

A chest radiograph and routine blood tests may indicate complications or precipitating causes and are often performed on admittance to an emergency department. New regional wall motion abnormalities on an echocardiogram are also suggestive of a myocardial infarction and are sometimes performed in equivocal cases.[38] Technetium and thallium can be used in nuclear medicine to visualize areas of reduced blood flow and tissue viability, respectively.[38][39] Technetium is used in a MUGA scan.

[edit] Diagnostic criteria

WHO criteria[40] have classically been used to diagnose MI; a patient is diagnosed with myocardial infarction if two (probable) or three (definite) of the following criteria are satisfied:

  1. Clinical history of ischaemic type chest pain lasting for more than 20 minutes
  2. Changes in serial ECG tracings
  3. Rise and fall of serum cardiac enzymes (biomarkers) such as creatine kinase, troponin I, and lactate dehydrogenase isozymes specific for the heart.

The WHO criteria were refined in 2000 to give more prominence to cardiac biomarkers.[41] According to the new guidelines, a cardiac troponin rise accompanied by either typical symptoms, pathological Q waves, ST elevation or depression or coronary intervention are diagnostic of MI.

[edit] Physical examination

The general appearance of patients may vary according to the experienced symptoms; the patient may be comfortable, or restless and in severe distress with an increased respiratory rate. A cool and pale skin is common and points to vasoconstriction. Some patients have low-grade fever (38–39 °C). Blood pressure may be elevated or decreased, and the pulse can be become irregular.[42][43]

If heart failure ensues, elevated jugular venous pressure and hepatojugular reflux, or swelling of the legs due to peripheral edema may be found on inspection. Rarely, a cardiac bulge with a pace different from the pulse rhythm can be felt on precordial examination. Various abnormalities can be found on auscultation, such as a third and fourth heart sound, systolic murmurs, paradoxical splitting of the second heart sound, a pericardial friction rub and rales over the lung.[42][44]

12-lead electrocardiogram (ECG) with ST-segment elevation in leads II, III and aVF, suggestive of an inferior acute myocardial infarction (AMI).
Enlarge
12-lead electrocardiogram (ECG) with ST-segment elevation in leads II, III and aVF, suggestive of an inferior acute myocardial infarction (AMI).

[edit] Electrocardiogram

The earliest electrocardiographic (ECG or EKG) finding resulting from acute myocardial infarction is the hyperacute T wave.[45] In practice this is rarely seen, because it only exists for 5-30 minutes after the onset of infarction.[citation needed] Findings suggestive of MI are elevations of the ST segment and changes in the T wave. ST segment elevation is usually evident within hours of the onset of symptoms. Later, there can be loss of R wave height and development of pathological Q waves. The T waves invert which may persist for many months or even permanently.[46]

In addition, the presence of a new left bundle branch block in the appropriate clinical setting is also indicative of an acute myocardial infarction.[47] After a myocardial infarction, changes can often be seen on the ECG called Q waves, representing scarred heart tissue. However, a normal ECG/EKG does not rule out a myocardial infarction.[48]

The ST segment elevation distinguishes between:

  • STEMI ("ST-Elevation Myocardial Infarction")
  • NSTEMI ("Non-ST-Elevation Myocardial Infarction") -- diagnosed when cardiac enzymes are elevated.

The leads with abnormalities on the ECG may help identify the location:[49]

Wall affected Leads Artery involved Reciprocal changes
Anterior V2-V4 Left coronary artery, Left Anterior descending (LAD) II, III, aVF
Anterolateral I, aVL, V3-V6 LAD and diagonal branches, circumflex and marginal branches II, III, aVF
Anteroseptal V1-V4 LAD -
Inferior II, III, aVF right coronary artery (RCA) I, aVL
Lateral I, aVL, V5, V6 circumflex branch or left coronary artery II, III, aVF
Posterior V8, V9 RCA or circumflex artery V1-V4 (R greater than S in V1 & V2, ST-segment depression, elevated T wave)
Right ventricular V4R-V6R RCA -

Left bundle branch block and pacing can interfere with the electrocardiographic diagnosis of coronary ischemia.

[edit] Cardiac markers

Main article: Cardiac marker

Cardiac markers or cardiac enzymes are proteins from cardiac tissue found in the blood. These proteins are released into the bloodstream when damage to the heart occurs, as in the case of a myocardial infarction. Until the 1980s, the enzymes SGOT and LDH were used to assess cardiac injury. Then it was found that disproportional elevation of the MB subtype of the enzyme creatine kinase (CK) was very specific for myocardial injury. Current guidelines are generally in favor of troponin sub-units I or T, which are very specific for the heart muscle and are thought to rise before permanent injury develops.[50] Elevated troponins in the setting of chest pain may accurately predict a high likelihood of a myocardial infarction in the near future.[51]

The diagnosis of myocardial infarction requires two out of three components (history, ECG, and enzymes). When damage to the heart occurs, levels of cardiac markers rise over time, which is why blood tests for them are taken over a 24 hour period. Because these enzyme levels are not elevated immediately following a heart attack, patients presenting with chest pain are generally treated with the assumption that a myocardial infarction has occurred and then evaluated for a more precise diagnosis.[52]

[edit] Angiography

Angiogram of the coronary arteries.
Enlarge
Angiogram of the coronary arteries.

In difficult cases or in situations where intervention to restore blood flow is appropriate, coronary angiography can be performed. A catheter is inserted into an artery (usually the femoral artery) and pushed to the vessels supplying the heart. Obstructed or narrowed arteries can be identified, and angioplasty applied as a therapeutic measure (see below). Angioplasty requires extensive skill, especially in emergency settings, and may not always be available out of hours. It is commonly performed by interventional cardiologists.

[edit] Histopathology

Microscopy image (magn. ca 100x, H&E stain) from autopsy specimen of myocardial infarct (7 days of duration).
Enlarge
Microscopy image (magn. ca 100x, H&E stain) from autopsy specimen of myocardial infarct (7 days of duration).

Histopathological examination of the heart may reveal infarction at autopsy. Under the microscope, myocardial infarction presents as a circumscribed area of ischemic, coagulative necrosis (cell death). On gross examination, the infarct is not identifiable within the first 12 hours.[53]

Although earlier changes can be discerned using electron microscopy, one of the earliest changes under a normal microscope are so-called wavy fibers.[54] Subsequently, the myocyte cytoplasm becomes more eosinophilic (pink) and the cells lose their transversal striations, with typical changes and eventually loss of the cell nucleus.[55] The interstitium at the margin of the infarcted area is initially infiltrated with neutrophils, then with lymphocytes and macrophages, who phagocytose ("eat") the myocyte debris. The necrotic area is surrounded and progressively invaded by granulation tissue, which will replace the infarct with a fibrous (collagenous) scar (which are typical steps in wound healing). The interstitial space (the space between cells outside of blood vessels) may be infiltrated with red blood cells.[53]

These features can be recognized in cases where the perfusion was not restored; reperfused infarcts can have other hallmarks, such as contraction band necrosis.[56]

[edit] First aid

As myocardial infarction is a common medical emergency, and the signs are often part of first aid courses. The emergency action principles also apply in the case of myocardial infarction.

[edit] Immediate care

When a heart attack is suspected, call for help immediately. When symptoms of MI occur, people wait on average 3 hours before seeking help.[57]

Certain positions allow the patient to rest in a position which minimizes breathing difficulties. A half-sitting position with knees bent is often recommended. Access to more oxygen can be given by opening the window and widening the collar for easier breathing.

Aspirin can be given quickly (if the patient is not allergic to aspirin); but taking aspirin before calling the emergency medical services may be associated with unwanted delay.[58] Aspirin has an antiplatelet effect which inhibits formation of further thrombi (blood clots) that clog arteries. Non-enteric coated or soluble preparations are preferred. If chewed or dissolved, respectively, they can be absorbed by the body even quicker. If the patient cannot swallow, the aspirin can be used sublingually. U.S. guidelines recommend a dose of 162 – 325 mg.[59] Australian guidelines recommend a dose of 150 – 300 mg.[60]

Glyceryl trinitrate (nitroglycerin) sublingually (under the tongue) can be given if it has been prescribed for the patient.

Other general first aid principles include monitoring pulse, breathing, level of consciousness and, if possible, the blood pressure of the patient. In case of cardiac arrest, cardiopulmonary resuscitation (CPR) can be administred.

[edit] Automatic external defibrillation (AED)

Since the publication of data showing that the availability of automated external defibrillators (AEDs) in public places may significantly increase chances of survival, many of these have been installed in public buildings, public transport facilities, and in non-ambulance emergency vehicles (e.g. police cars and fire engines). AEDs analyze the heart's rhythm and determine whether the rhythm is amenable to defibrillation ("shockable"), as in ventricular tachycardia and ventricular fibrillation.

[edit] Emergency services

Emergency services may recommend the patient to take nitroglycerin tablets or patches, in case these are available, particularly if they had prior heart attacks or angina.

In an ambulance, an intravenous line is established, and the patient is transported immediately if breathing and pulse are present. Oxygen first aid is provided and the patient is calmed. Close cardiac monitoring (with an electrocardiogram) is initiated if available.

If the patient has lost breathing or circulation advanced cardiac life support (including defibrillation) may be necessary and (at the paramedic level) injection of medications may be given per protocol. CPR is performed if there is no satisfactory cardiac output.

About 20% of patients die before they reach the hospital — the cause of death is often ventricular fibrillation.

[edit] Wilderness first aid

In wilderness first aid, a possible heart attack justifies evacuation by the fastest available means, including MEDEVAC, even in the earliest or precursor stages. The patient will rapidly be incapable of further exertion and have to be carried out.

[edit] Air travel

Certified personel traveling by commercial aircraft may be able to assist an MI patient by using the on-board first aid kit, which may contain some cardiac drugs (such as glyceryl trinitrate spray, aspirin, or opioid painkillers) and oxygen. Pilots may divert the flight to land at a nearby airport. Cardiac monitors are being introduced by some airlines, and they can be used by both on-board and ground-based physicians.[61]

[edit] Treatment

A heart attack is a medical emergency which demands both immediate attention and activation of the emergency medical services. The ultimate goal of the management in the acute phase of the disease is to salvage as much myocardium as possible and prevent further complications. As time passes, the risk of damage to the heart muscle increases; hence the phrase that in myocardial infarction, "time is muscle", and time wasted is muscle lost.[62]

The treatments itself may have complications. If attempts to restore the blood flow are initiated after a critical period of only a few hours, the result is reperfusion injury instead of amelioration.[63] Other treatment modalities may also cause complications; the use of antithrombotics for example carries an increased risk of bleeding.

[edit] First line

In the hospital, oxygen, aspirin, glyceryl trinitrate (nitroglycerin) and analgesia (usually morphine, hence the popular mnemonic MONA, morphine, oxygen, nitro, aspirin) are administered as soon as possible. In many areas, first responders can be trained to administer these prior to arrival at the hospital.

Of the first line agents used, the only one which has been proven to decrease mortality is aspirin.[64]

[edit] Reperfusion

Individuals with ST elevation (known as ST elevation myocardial infarctions or STEMIs) are typically offered urgent therapies to restore blood flow to the infarct zone (reperfusion). These include thrombolytic agents, percutaneous coronary intervention or bypass surgery. Individuals without ST elevations (known as non-ST elevation myocardial infarctions or NSTEMIs) are often stabilized with antiplatelet drugs and anticoagulated. If there condition remains (hemodynamically) stable, they can be offered either late coronary angiography with subsequent restoration of blood flow (revascularization), or non-invasive stress testing to determine if there is significant ischemia that would benefit from revascularization.

The basis for this distinction in treatment regimens is that ST segment elevations on an ECG are typically due to complete occlusion of a coronary artery. On the other hand, in NSTEMIs there is typically a sudden narrowing of a coronary artery with preserved (but diminished) flow to the distal myocardium. Anticoagulation and antiplatelet agents are given to prevent the narrowed artery from occluding.

At least 10% of patients with STEMI don't develop myocardial necrosis (as evidenced by a rise in cardiac markers) after reperfusion therapy. Such a succesfull restoration of flow to the infarct-related artery during an acute myocardial infarction is known as "aborting" the myocardial infarction. If treated within the hour, about 25% of STEMIs can be aborted.[65]

[edit] Thrombolytic therapy

Thrombolytic drugs are indicated for the treatment of STEMIs if they can be administered within 12 hours of the onset of symptoms.[59] Their effectiveness is highest in the first 2 hours after the artery is occluded and rapidly decreases after that.[citation needed] After 12 hours, it is generally believed that the risks associated with thrombolytic agents outweigh any benefit they may have to open up the infarct-related artery.[citation needed] Because irreversible ischemic injury occurs within 2–4 hours of the infarction, there is a limited window of time available for reperfusion to work. When reperfusion occurs later, this may result in reperfusion injury.

Thrombolytic agents include streptokinase, urokinase, and alteplase (recombinant tissue plasminogen activator, rtPA). More recently, thrombolytic agents similar in structure to rtPA such as reteplase and tenecteplase have been used. These newer agents boast efficacy at least as good as rtPA with significantly easier administration. The thrombolytic agent used in a particular individual is based on institution preference and the age of the patient.

Depending on the thrombolytic agent being used, adjuvant anticoagulation with heparin or low molecular weight heparin may be of benefit.[66][67] With tPA and related agents (reteplase and tenecteplase), heparin is needed to maintain coronary artery patency. Because of the anticoagulant effect of fibrinogen depletion with streptokinase[68] and urokinase[69][70][71] treatment, it is less necessary there.[66]

Thrombolytic therapy to abort a myocardial infarction is not always effective, and has a 10-20% failure rate.[citation needed] In cases of failure of the thrombolytic agent to open the infarct-related coronary artery, the patient is then either treated conservatively with anticoagulants and allowed to "complete the infarction" or percutaneous coronary intervention (PCI, see below) is then performed. Percutaneous coronary intervention in this setting is known as "rescue PCI" or "salvage PCI". Complications, particularly bleeding, are significantly higher with rescue PCI than with primary PCI due to the action of the thrombolytic agent.

[edit] Percutaneous coronary intervention

Although clinical trials suggest better outcomes compared to thrombolytic therapy, logistic and economic obstacles seem to hinder a more widespread application of percutaneous coronary intervention (PCI) via cardiac catheterization.[72] The use of percutaneous coronary intervention as a therapy to abort a myocardial infarction is known as primary PCI. The goal of primary PCI is to open the artery as soon as possible, and preferably within 90 minutes of the patient presenting to the emergency room. This time is referred to as the door-to-balloon time. Few hospitals can provide PCI within the 90 minute interval.[73]

The current guidelines in the United States restrict primary PCI to hospitals with available emergency bypass surgery as a backup[59], but this is not the case in other parts of the world.[citation needed]

[edit] Coronary artery bypass surgery

Emergency coronary surgery, in the form of coronary artery bypass surgery is another option, if cardiothoracic surgery services are available. In these heart bypass operations, an artery or vein from the patient is implanted on the aorta to bypass narrowings or occlusions on the coronary arteries. Several arteries and veins can be used, however internal mammary artery grafts have demonstrated significantly better long-term patency rates than great saphenous vein grafts.[74] In patients with two or more coronary arteries affected, bypass surgery is associated with higher long-term survival rates compared to percutaneous interventions.[75] In patients with single vessel disease, surgery is comparably safe and effective, and may be a treatment option in selected cases.[76] Bypass surgery has higher costs initially, but becomes cost-effective in the long term.[77] A surgical bypass graft is more invasive initially but bears less risk of recurrent procedures (but these may be again minimally invasive).[76]

[edit] Monitoring for arrhythmias

Additional objectives are to prevent life-threatening arrhythmias or conduction disturbances. This requires monitoring in a coronary care unit and protocolised administration of antiarrhythmic agents. Antiarrhythmic agents are typically only given to individuals with life-threatening arrhythmias after a myocardial infarction and not to suppress the ventricular ectopy that is often seen after a myocardial infarction.[78][79][80]

[edit] Rehabilitation

Cardiac rehabilitation aims to optimize function and quality of life in those afflicted with a heart disease. This can be with the help of a physician, or in the form of a cardiac rehabilitation program.[81]

Physical exercise is an important part of rehabilitation after a myocardial infarction, with beneficial effects on cholesterol levels, blood pressure, weight, stress and mood.[81] Some patients become afraid of exercising because it might trigger another infarct.[82] Patients are stimulated to exercise, and should only avoid certain exerting activities such as shovelling. Local authorities may place limitations on driving motorised vehicles.[83] Some people are afraid to have sex after a heart attack. Most people can resume sexual activities after 3 to 4 weeks. The amount of activity needs to be dosed to the patients possibilities.[84]

[edit] Secondary prevention

The risk of a recurrent myocardial infarction decreases with strict blood pressure management and lifestyle changes, chiefly smoking cessation, regular exercise, a sensible diet for patients with heart disease, and limitation of alcohol intake.

Patients are usually commenced on several long-term medications post-MI, with the aim of preventing secondary cardiovascular events such as further myocardial infarctions, congestive heart failure or cerebrovascular accident (CVA). Unless contraindicated, such medications may include:[85][60]

  • Antiplatelet drug therapy such as aspirin and/or clopidogrel should be continued to reduce the risk of plaque rupture and recurrent myocardial infarction. Aspirin is first-line, owing to its low cost and comparable efficacy, with clopidogrel reserved for patients intolerant of aspirin. The combination of clopidogrel and aspirin may further reduce risk of cardiovascular events, however the risk of hemorrhage is increased.[86]
  • Beta blocker therapy such as metoprolol or carvedilol should be commenced.[87] These have been particularly beneficial in high-risk patients such as those with left ventricular dysfunction and/or continuing cardiac ischaemia.[88] β-Blockers decrease mortality and morbidity. They also improve symptoms of cardiac ischemia in NSTEMI.
  • ACE inhibitor therapy should be commenced 24–48 hours post-MI in hemodynamically-stable patients, particularly in patients with a history of MI, diabetes mellitus, hypertension, anterior location of infarct (as assessed by ECG), and/or evidence of left ventricular dysfunction. ACE inhibitors reduce mortality, the development of heart failure, and decrease ventricular remodelling post-MI.[89]
  • Statin therapy has been shown to reduce mortality and morbidity post-MI.[90][91] The effects of statins may be more than their LDL lowering effects. The general consensus is that statins have plaque stabilization and multiple other ("pleiotropic") effects that may prevent myocardial infarction in addition to their effects on blood lipids.[92]
  • The aldosterone antagonist agent eplerenone has been shown to further reduce risk of cardiovascular death post-MI in patients with heart failure and left ventricular dysfunction, when used in conjunction with standard therapies above.[93]
  • Omega-3 fatty acids, commonly found in fish, have been shown to reduce mortality post-MI.[94] While the mechanism by which these fatty acids decrease mortality is unknown, it has been postulated that the survival benefit is due to electrical stabilization and the prevention of ventricular fibrillation.[95] However, further studies in a high-risk subset have not shown a clear-cut decrease in potentially fatal arrhythmias due to omega-3 fatty acids.[96][97]

[edit] New therapies under investigation

Patients who receive stem cell treatment by coronary artery injections of stem cells derived from their own bone marrow after a myocardial infarction (MI) show improvements in left ventricular ejection fraction and end-diastolic volume not seen with placebo. The larger the initial infarct size, the greater the effect of the infusion. Clinical trials of progenitor cell infusion as a treatment approach to ST elevation MI are proceeding.[98]

There are currently 3 biomaterial and tissue engineering approaches for the treatment of MI, but these are in an even earlier stage of medical research, so many questions and issues need to be addressed before they can be applied to patients. The first involves polymeric left ventricular restraints in the prevention of heart failure. The second utilizes in vitro engineered cardiac tissue, which is subsequently implanted in vivo. The final approach entails injecting cells and/or a scaffold into the myocardium to create in situ engineered cardiac tissue.[99]

[edit] Complications

Complications may occur immediately following the heart attack (in the acute phase), or may need time to develop (a chronic problem). After an infarction, an obvious complication is a second infarction, which may occur in the domain of another atherosclerotic coronary artery, or in the same zone if there are any live cells left in the infarct.

A myocardial infarction may compromise the function of the heart as a pump for the circulation, a state called heart failure. There are different types of heart failure; left- or right-sided (or bilateral) heart failure may occur depending on the affected part of the heart, and it is a low-output type of failure. If one of the heart valves is affected, this may cause dysfunction, such as mitral regurgitation in the case of left-sided MI.

Myocardial rupture is most common three to five days after myocardial infarction, commonly of small degree, but may occur one day to three weeks later, in as many as 10% of all MIs. This may occur in the free walls of the ventricles, the septum between them, the papillary muscles, or less commonly the atria. Rupture occurs because of increased pressure against the weakened walls of the heart chambers due to heart muscle that cannot pump blood out effectively. The weakness may also lead to ventricular aneurysm, a localized dilation or ballooning of the heart chamber.

Rupture is usually a catastrophic event that may result a life-threatening process known as cardiac tamponade, in which blood accumulates within the pericardium or heart sac, and compresses the heart to the point where it cannot pump effectively. Rupture of the intraventricular septum (the muscle separating the left and right ventricles) causes a ventricular septal defect with shunting of blood through the defect from the left side of the heart to the right side of the heart. Rupture of the papillary muscle may also lead to acute mitral regurgitation and subsequent pulmonary edema and possibly even cardiogenic shock.

A 12 lead electrocardiogram showing ventricular tachycardia.
Enlarge
A 12 lead electrocardiogram showing ventricular tachycardia.

Since the electrical characteristics of the infarcted tissue change (see pathophysiology section), arrhythmias are a frequent complication. The re-entry phenomenon may cause too fast heart rates (ventricular tachycardia and even ventricular fibrillation), and lesions at the site of the sinoatrial node may cause a complete heart block (when the impulse from the atrioventricular node, the normal cardiac pacemaker, doesn't reach the heart chambers any more). Both cause the blood flow to decrease, and stagnating blood starts to clot. These blood clots may enter the circulation and get trapped when the vessel diameter decreases (for example in the lung, causing pulmonary embolism).

As a reaction to the damage of the heart muscle, inflammatory cells are attracted. The inflammation may reach out and affect the heart sac. This is called pericarditis. In Dressler's syndrome, this occurs several weeks after the initial event.

The final state can be cardiogenic shock (inadequate circulation of blood and oxygen delivery due to primary failure of the ventricles of the heart to function effectively) and death.

[edit] Prognosis

The prognosis for patients after a myocardial infarction depends largely on infarct size, left ventricular function and the presence or absence of ventricular arrhythmias.[100] Prognosis is significantly worsened if a mechanical complication (papillary muscle rupture, myocardial free wall rupture, and so on) were to occur.

[edit] Legal implications

At common law, a myocardial infarction is generally a disease, but may sometimes be an injury. This has implications for no-fault insurance schemes such as workers' compensation. A heart attack is generally not covered;[101] however, it may be a work-related injury if it results, for example, from unusual emotional stress or unusual exertion.[102][103] Additionally, in some jurisdictions, heart attacks suffered by persons in particular occupations such as police officers may be classified as line-of-duty injuries by statute or policy. In some countries or states, a person who has suffered from a myocardial infarction may be prevented from participating in activity that puts other people's lives at risk, for example driving a car, taxi or airplane.[83]

[edit] See also

[edit] References

  1. ^ a b World Health Organization. Annex Table 2: Deaths by cause, sex and mortality stratum in WHO regions, estimates for 2002 The world health report 2004.
  2. ^ Cause of Death - UC Atlas of Global Inequality. Retrieved December 7, 2006.
  3. ^ Deaths and percentage of total deaths for the 10 leading causes of death: United States, 2002-2003 PDF - from the National Center of Health Statistics.
  4. ^ Heart Attack and Angina Statistics (2003) - from the American Heart Association. Retrieved December 7, 2006.
  5. ^ eMedicine med/1568 - Retrieved December 7, 2006.
  6. ^ a b Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. "Prediction of coronary heart disease using risk factor categories". Circulation 1998; 97(18): 1837-47. PMID 9603539
  7. ^ Yusuf S, Hawken S, Ounpuu S, Bautista L, Franzosi MG, Commerford P, Lang CC, Rumboldt Z, Onen CL, Lisheng L, Tanomsup S, Wangai P Jr, Razak F, Sharma AM, Anand SS; INTERHEART Study Investigators. "Obesity and the risk of myocardial infarction in 27,000 participants from 52 countries: a case-control study." Lancet 2005; 366(9497): 1640-9. PMID 16271645
  8. ^ Jensen G, Nyboe J, Appleyard M, Schnohr P. "Risk factors for acute myocardial infarction in Copenhagen, II: Smoking, alcohol intake, physical activity, obesity, oral contraception, diabetes, lipids, and blood pressure." Eur Heart J 1991; 12(3): 298-308. PMID 2040311
  9. ^ a b Nyboe J, Jensen G, Appleyard M, Schnohr P. "Risk factors for acute myocardial infarction in Copenhagen. I: Hereditary, educational and socioeconomic factors. Copenhagen City Heart Study". Eur Heart J 1989; 10(10): 910-6. PMID 2598948
  10. ^ Khader YS, Rice J, John L, Abueita O. "Oral contraceptives use and the risk of myocardial infarction: a meta-analysis". Contraception 2003; 68(1):11-7. PMID 12878281
  11. ^ a b Wilson AM, Ryan MC, Boyle AJ. "The novel role of C-reactive protein in cardiovascular disease: risk marker or pathogen". Int J Cardiol 2006; 106(3): 291-7. PMID 16337036
  12. ^ Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon RO 3rd, Criqui M, Fadl YY, Fortmann SP, Hong Y, Myers GL, Rifai N, Smith SC Jr, Taubert K, Tracy RP, Vinicor F. "Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association." Circulation 2003; 107(3): 499-511. PMID 12551878
  13. ^ Janket SJ, Baird AE, Chuang SK, Jones JA. "Meta-analysis of periodontal disease and risk of coronary heart disease and stroke." Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2003; 95(5):559-69. PMID 12738947
  14. ^ Pihlstrom BL, Michalowicz BS, Johnson NW. "Periodontal diseases". Lancet 2005; 366(9499): 1809-20. PMID 16298220
  15. ^ Scannapieco FA, Bush RB, Paju S. "Associations between periodontal disease and risk for atherosclerosis, cardiovascular disease, and stroke. A systematic review." Ann Periodontol 2003; 8(1):38-53. PMID 14971247
  16. ^ D'Aiuto F, Parkar M, Nibali L, Suvan J, Lessem J, Tonetti MS. "Periodontal infections cause changes in traditional and novel cardiovascular risk factors: results from a randomized controlled clinical trial". Am Heart J 2006; 151(5): 977-84. PMID 16644317
  17. ^ Lourbakos A, Yuan YP, Jenkins AL, Travis J, Andrade-Gordon P, Santulli R, Potempa J, Pike RN. "Activation of protease-activated receptors by gingipains from Porphyromonas gingivalis leads to platelet aggregation: a new trait in microbial pathogenicity." Blood 2001; 97(12): 3790-7. PMID 11389018
  18. ^ Qi M, Miyakawa H, Kuramitsu HK. "Porphyromonas gingivalis induces murine macrophage foam cell formation." Microb Pathog 2003; 35(6): 259-67. PMID 14580389
  19. ^ Spahr A, Klein E, Khuseyinova N, Boeckh C, Muche R, Kunze M, Rothenbacher D, Pezeshki G, Hoffmeister A, Koenig W. "Periodontal infections and coronary heart disease: role of periodontal bacteria and importance of total pathogen burden in the Coronary Event and Periodontal Disease (CORODONT) study." Arch Intern Med 2006; 166(5): 554-9. PMID 16534043
  20. ^ Lichstein E, Chadda KD, Naik D, Gupta PK. (1974). "Diagonal ear-lobe crease: prevalence and implications as a coronary risk factor.". N Engl J Med 290 (11): 615-6. PMID 4812503.
  21. ^ Miric D, Fabijanic D, Giunio L, Eterovic D, Culic V, Bozic I, Hozo I. "Dermatological indicators of coronary risk: a case-control study". Int J Cardiol 1998; 67(3): 251-5. PMID 2040311
  22. ^ P A J Krijnen et al. Apoptosis in myocardial ischaemia and infarction. Journal of Clinical Pathology 2002;55:801-811. PMID 12401816
  23. ^ ICD-10: Ischaemic heart diseases. World Health Organization, 2006. Retrieved November 25, 2006.
  24. ^ Dorland's Illustrated Medical Dictionary. Retrieved November 25, 2006.
  25. ^ a b (2001) Rubin's Pathology - Clinicopathological Foundations of Medicine. Maryland: Lippincott Williams & Wilkins, p. 525. ISBN 0-7817-4733-3.
  26. ^ (2001) Rubin's Pathology - Clinicopathological Foundations of Medicine. Maryland: Lippincott Williams & Wilkins, p. 545. ISBN 0-7817-4733-3.
  27. ^ Moon JC, De Arenaza DP, Elkington AG, Taneja AK, John AS, Wang D, Janardhanan R, Senior R, Lahiri A, Poole-Wilson PA, Pennell DJ. (2004). "The pathologic basis of Q-wave and non-Q-wave myocardial infarction: a cardiovascular magnetic resonance study.". J Am Coll Cardiol 44 (3): 554-60. PMID 15358019.
  28. ^ Yang H, Pu M, Rodriguez D, Underwood D, Griffin BP, Kalahasti V, Thomas JD, Brunken RC (2004). "Ischemic and viable myocardium in patients with non-Q-wave or Q-wave myocardial infarction and left ventricular dysfunction: a clinical study using positron emission tomography, echocardiography, and electrocardiography.". J Am Coll Cardiol 43 (4): 592-8. PMID 14975469.
  29. ^ Goodman SG, Langer A, Ross AM, Wildermann NM, Barbagelata A, Sgarbossa EB, Wagner GS, Granger CB, Califf RM, Topol EJ, Simoons ML, Armstrong PW. (1998). "Non-Q-wave versus Q-wave myocardial infarction after thrombolytic therapy: angiographic and prognostic insights from the global utilization of streptokinase and tissue plasminogen activator for occluded coronary arteries-I angiographic substudy. GUSTO-I Angiographic Investigators.". Circulation 97 (5): 444-50. PMID 9490238.
  30. ^ National Heart, Lung and Blood Institute. Heart Attack Warning Signs. Retrieved November 22, 2006.
  31. ^ Acute Coronary Syndrome. American Heart Association. Retrieved November 25, 2006.
  32. ^ McSweeney JC, Cody M, O'Sullivan P, Elberson K, Moser DK, Garvin BJ (2003). "Women's early warning symptoms of acute myocardial infarction". Circulation 108 (21): 2619-23. PMID 14597589.
  33. ^ D Lee, D Kulick, J Marks. Heart Attack (Myocardial Infarction) by MedicineNet.com . Retrieved November 28, 2006.
  34. ^ Spodick DH (2004). "Decreased recognition of the post-myocardial infarction (Dressler) syndrome in the postinfarct setting: does it masquerade as "idiopathic pericarditis" following silent infarcts?". Chest 126 (5): 1410-1. PMID 15539705.
  35. ^ a b Davis TM, Fortun P, Mulder J, Davis WA, Bruce DG (2004). "Silent myocardial infarction and its prognosis in a community-based cohort of Type 2 diabetic patients: the Fremantle Diabetes Study". Diabetologia 47 (3): 395-9. PMID 14963648.
  36. ^ (2001) Rubin's Pathology - Clinicopathological Foundations of Medicine. Maryland: Lippincott Williams & Wilkins, p. 549. ISBN 0-7817-4733-3.
  37. ^ Myocardial infarction: diagnosis and investigations - GPnotebook, retrieved November 27, 2006.
  38. ^ a b DE Fenton et. al. Myocardial infarction - eMedicine, retrieved November 27, 2006.
  39. ^ HEART SCAN - Patient information from University College London. Retrieved November 27, 2006.
  40. ^ Gillum RF, Fortmann SP, Prineas RJ, Kottke TE. International diagnostic criteria for acute myocardial infarction and acute stroke. Am Heart J 1984;108:150-8. PMID 6731265
  41. ^ Alpert JS, Thygesen K, Antman E, Bassand JP. Myocardial infarction redefined--a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. J Am Coll Cardiol 2000;36:959-69. PMID 10987628.
  42. ^ a b S. Garas et. al.. Myocardial Infarction. eMedicine. Retrieved November 22, 2006.
  43. ^ Kasper DL, Braunwald E, Fauci AS, Hauser SL, Longo DL, Jameson JL. Harrison's Principles of Internal Medicine. p. 1444. New York: McGraw-Hill, 2005. ISBN 0-07-139140-1.
  44. ^ Kasper DL, et. al. Harrison's Principles of Internal Medicine. p. 1450.
  45. ^ Somers MP, Brady WJ, Perron AD, Mattu A. "The prominant T wave: electrocardiographic differential diagnosis." Am J Emerg Med 2002; 20(3): 243-51. PMID 11992348
  46. ^ Morris F, Brady W (2002). "ABC of clinical electrocardiography: Acute myocardial infarction-Part I.". BMJ 324 (7341): 831-4. PMID 11934778.Full text
  47. ^ Edhouse J, Brady W, Morris F (2002). "ABC of clinical electrocardiography: Acute myocardial infarction-Part II.". BMJ 324 (7343): 963-6. PMID 11964344.Full text
  48. ^ Herring N, Paterson D (2006). "ECG diagnosis of acute ischaemia and infarction: past, present and future.". QJM 99 (4): 219-30. PMID 16495300.
  49. ^ Springhouse,. ECG Facts Made Incredibly Quick! (Incredibly Easy! Series). Hagerstwon, MD: Lippincott Williams & Wilkins. ISBN 1-58255-672-5.
  50. ^ Eisenman A (2006). "Troponin assays for the diagnosis of myocardial infarction and acute coronary syndrome: where do we stand?". Expert Rev Cardiovasc Ther 4 (4): 509-14. PMID 16918269.
  51. ^ Aviles RJ, Askari AT, Lindahl B, Wallentin L, Jia G, Ohman EM, Mahaffey KW, Newby LK, Califf RM, Simoons ML, Topol EJ, Berger P, Lauer MS (2002). "Troponin T levels in patients with acute coronary syndromes, with or without renal dysfunction.". N Engl J Med 346 (26): 2047-52. PMID 12087140.. Summary for laymen
  52. ^ Braunwald E, Antman EM, Beasley JW, Califf RM, Cheitlin MD, Hochman JS, Jones RH, Kereiakes D, Kupersmith J, Levin TN, Pepine CJ, Schaeffer JW, Smith EE III, Steward DE, Théroux P. (2002). "ACC/AHA 2002 guideline update for the management of patients with unstable angina and non–ST-segment elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable Angina).". J Am Coll Cardiol 40: 1366-74. PMID 12383588.
  53. ^ a b (2001) Rubin's Pathology - Clinicopathological Foundations of Medicine. Maryland: Lippincott Williams & Wilkins, p. 546. ISBN 0-7817-4733-3.
  54. ^ Eichbaum FW. "'Wavy' myocardial fibers in spontaneous and experimental adrenergic cardiopathies" Cardiology 1975; 60(6): 358–65. PMID 782705
  55. ^ S Roy. Myocardial infarction. Retrieved November 28, 2006.
  56. ^ Fishbein MC. Reperfusion injury. Clin Cardiol 1990; 13(3):213-7. PMID 2182247.
  57. ^ Heart attack first aid. MedlinePlus. Retrieved December 3, 2006.
  58. ^ Brown AL, Mann NC, Daya M, Goldberg R, Meischke H, Taylor J, Smith K, Osganian S, Cooper L. (2000). "Demographic, belief, and situational factors influencing the decision to utilize emergency medical services among chest pain patients. Rapid Early Action for Coronary Treatment (REACT) study.". Circulation 102 (2): 173-8. PMID 10889127.
  59. ^ a b c Antman EM, Anbe DT, Armstrong PW, Bates ER, Green LA, Hand M,Hochman JS, Krumholz HM, Kushner FG, Lamas GA, Mullany CJ, Ornato JP,Pearle DL, Sloan MA, Smith SC Jr (2004). "ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction)". J Am Coll Cardiol 44: 671-719. PMID 15358045.
  60. ^ a b Rossi S, editor. Australian Medicines Handbook 2006. Adelaide: Australian Medicines Handbook; 2006. ISBN 0-9757919-2-3.
  61. ^ Dowdall N. "'Is there a doctor on the aircraft?' Top 10 in-flight medical emergencies." BMJ 2000; 321(7272):1336-7. PMID 11090520. Full text at PMC: 11090520
  62. ^ TIME IS MUSCLE TIME WASTED IS MUSCLE LOST. Early Heart Attack Care, St. Agnes Healthcare. Retrieved November 29, 2006.
  63. ^ Faxon DP. "Coronary interventions and their impact on post myocardial infarction survival." Clin Cardiol 2005; 28(11 Suppl 1):I38-44. PMID 16450811
  64. ^ ISIS-2 Collaborative group (1988). "Randomized trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2.". Lancet (2): 349-60. PMID 2899772.
  65. ^ Verheugt FW, Gersh BJ, Armstrong PW. "Aborted myocardial infarction: a new target for reperfusion therapy." Eur Heart J 2006; 27(8): 901-4. PMID 16543251
  66. ^ a b The GUSTO investigators (1993). "An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. The GUSTO investigators.". N Engl J Med 329 (10): 673-82. PMID 8204123.
  67. ^ Sabatine MS, Morrow DA, Montalescot G, Dellborg M, Leiva-Pons JL, Keltai M, Murphy SA, McCabe CH, Gibson CM, Cannon CP, Antman EM, Braunwald E; Clopidogrel as Adjunctive Reperfusion Therapy (CLARITY)-Thrombolysis in Myocardial Infarction (TIMI) 28 Investigators. (2005). "Angiographic and clinical outcomes in patients receiving low-molecular-weight heparin versus unfractionated heparin in ST-elevation myocardial infarction treated with fibrinolytics in the CLARITY-TIMI 28 Trial.". Circulation 112 (25): 3846-54. PMID 16291601.
  68. ^ Cowley MJ, Hastillo A, Vetrovec GW, Fisher LM, Garrett R, Hess ML. (1983). "Fibrinolytic effects of intracoronary streptokinase administration in patients with acute myocardial infarction and coronary insufficiency.". Circulation 67 (5): 1031-8. PMID 6831667.
  69. ^ Lourenco DM, Dosne AM, Kher A, Samama M. (1989). "Effect of standard heparin and a low molecular weight heparin on thrombolytic and fibrinolytic activity of single-chain urokinase plasminogen activator in vitro.". Thromb Haemost 62 (3): 923-6. PMID 2556812.
  70. ^ Van de Werf F, Vanhaecke J, de Geest H, Verstraete M, Collen D. (1986). "Coronary thrombolysis with recombinant single-chain urokinase-type plasminogen activator in patients with acute myocardial infarction.". Circulation 74 (5): 1066-70. PMID 2429783.
  71. ^ Bode C, Schoenermark S, Schuler G, Zimmermann R, Schwarz F, Kuebler W. (1988). "Efficacy of intravenous prourokinase and a combination of prourokinase and urokinase in acute myocardial infarction.". Am J Cardiol 61 (13): 971-4. PMID 2452564.
  72. ^ Boersma E; The Primary Coronary Angioplasty vs. Thrombolysis Group. "Does time matter? A pooled analysis of randomized clinical trials comparing primary percutaneous coronary intervention and in-hospital fibrinolysis in acute myocardial infarction patients." Eur Heart J 2006; 27(7):779-88. PMID 16513663
  73. ^ Bradley EH, Herrin J, Wang Y, Barton BA, Webster TR, Mattera JA, Roumanis SA, Curtis JP, Nallamothu BK, Magid DJ, McNamara RL, Parkosewich J, Loeb JM, Krumholz HM. "Strategies for reducing the door-to-balloon time in acute myocardial infarction." N Engl J Med 2006; 355(22): 2308-20. PMID 17101617
  74. ^ Raja SG, Haider Z, Ahmad M, Zaman H. "Saphenous vein grafts: to use or not to use?" Heart Lung Circ 2004; 13(4): 403-9. PMID 16352226
  75. ^ Hannan EL, Racz MJ, Walford G, Jones RH, Ryan TJ, Bennett E, Culliford AT, Isom OW, Gold JP, Rose EA. "Long-term outcomes of coronary-artery bypass grafting versus stent implantation." N Engl J Med 2005; 352(21): 2174-83. PMID 15917382
  76. ^ a b Bourassa MG. "Clinical trials of coronary revascularization: coronary angioplasty vs. coronary bypass grafting." Curr Opin Cardiol 2000; 15(4):281-6. PMID 11139092
  77. ^ Hlatky MA, Boothroyd DB, Melsop KA, Brooks MM, Mark DB, Pitt B, Reeder GS, Rogers WJ, Ryan TJ, Whitlow PL, Wiens RD. "Medical costs and quality of life 10 to 12 years after randomization to angioplasty or bypass surgery for multivessel coronary artery disease." Circulation 2004; 110(14):1960-6. PMID 15451795
  78. ^ Echt DS, Liebson PR, Mitchell LB, Peters RW, Obias-Manno D, Barker AH, Arensberg D, Baker A, Friedman L, Greene HL, et al. (1991). "Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial.". N Engl J Med 324 (12): 781-8. PMID 1900101.
  79. ^ Waldo AL, Camm AJ, deRuyter H, Friedman PL, MacNeil DJ, Pauls JF, Pitt B, Pratt CM, Schwartz PJ, Veltri EP. (1996). "Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. The SWORD Investigators. Survival With Oral d-Sotalol.". Lancet 348 (9019): 7-12. PMID 8691967.
  80. ^ Julian DG, Camm AJ, Frangin G, Janse MJ, Munoz A, Schwartz PJ, Simon P. (1997). "Randomised trial of effect of amiodarone on mortality in patients with left-ventricular dysfunction after recent myocardial infarction: EMIAT. European Myocardial Infarct Amiodarone Trial Investigators.". Lancet 349 (9053): 667-74. PMID 9078197.
  81. ^ a b Life after a Heart Attack. U.S. National Heart, Lung and Blood Institute. Retrieved December 2, 2006.
  82. ^ Trisha Macnair. Recovering after a heart attack. BBC, December 2005. Retrieved December 2, 2006.
  83. ^ a b Life After a Heart Attack. Health Professionals in Capital Health, Queen Elizabeth II Health Sciences Centre Halifax, Nova Scotia. Retrieved November 22, 2006.
  84. ^ "Heart Attack: Getting Back Into Your Life After a Heart Attack". American Academy of Family Physicians, updated March 2005. Retrieved December 4, 2006.
  85. ^ Smith A, Aylward P, Campbell T, et al. Therapeutic Guidelines: Cardiovascular, 4th edition. North Melbourne: Therapeutic Guidelines; 2003. ISSN 1327-9513
  86. ^ Peters RJ, Mehta SR, Fox KA, Zhao F, Lewis BS, Kopecky SL, Diaz R, Commerford PJ, Valentin V, Yusuf S; Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) Trial Investigators. (2003). "Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: observations from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study.". Circulation 108 (14): 1682-7. PMID 14504182.
  87. ^ Yusuf S, Peto R, Lewis J, Collins R, Sleight P. Beta blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis 1985;27:335-71. PMID 2858114
  88. ^ Dargie HJ. (2001). "Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial.". Lancet 357 (9266): 1385-90. PMID 11356434.
  89. ^ Pfeffer MA, Braunwald E, Moye LA, Basta L, Brown EJ Jr, Cuddy TE, Davis BR, Geltman EM, Goldman S, Flaker GC, et al (1992). "Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators.". N Engl J Med. 327 (10): 669-77. PMID 1386652.
  90. ^ Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica JW, Arnold JM, Wun CC, Davis BR, Braunwald E. (1996). "The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators.". N Engl J Med 335 (14): 1001-9. PMID 8801446.
  91. ^ Sacks FM, Moye LA, Davis BR, Cole TG, Rouleau JL, Nash DT, Pfeffer MA, Braunwald E. (1998). "Relationship between plasma LDL concentrations during treatment with pravastatin and recurrent coronary events in the Cholesterol and Recurrent Events trial.". Circulation 97 (15): 1446-52. PMID 9576424.
  92. ^ Ray KK, Cannon CP. "The potential relevance of the multiple lipid-independent (pleiotropic) effects of statins in the management of acute coronary syndromes." J Am Coll Cardiol 2005;46(8):1425-33. PMID 16226165
  93. ^ Keating G, Plosker G (2004). "Eplerenone : a review of its use in left ventricular systolic dysfunction and heart failure after acute myocardial infarction.". Drugs 64 (23): 2689-707. PMID 15537370.
  94. ^ (2001) "Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico.". Lancet 354 (9177): 447-55. PMID 10465168.
  95. ^ Leaf A, Albert C, Josephson M, Steinhaus D, Kluger J, Kang J, Cox B, Zhang H, Schoenfeld D (2005). "Prevention of fatal arrhythmias in high-risk subjects by fish oil n-3 fatty acid intake". Circulation 112 (18): 2762-8. PMID 16267249.
  96. ^ Brouwer IA, Zock PL, Camm AJ, Bocker D, Hauer RN, Wever EF, Dullemeijer C, Ronden JE, Katan MB, Lubinski A, Buschler H, Schouten EG; SOFA Study Group. (2006). "Effect of fish oil on ventricular tachyarrhythmia and death in patients with implantable cardioverter defibrillators: the Study on Omega-3 Fatty Acids and Ventricular Arrhythmia (SOFA) randomized trial.". JAMA 295 (22): 2613-9. PMID 16772624.
  97. ^ Raitt MH, Connor WE, Morris C, Kron J, Halperin B, Chugh SS, McClelland J, Cook J, MacMurdy K, Swenson R, Connor SL, Gerhard G, Kraemer DF, Oseran D, Marchant C, Calhoun D, Shnider R, McAnulty J. (2005). "Fish oil supplementation and risk of ventricular tachycardia and ventricular fibrillation in patients with implantable defibrillators: a randomized controlled trial.". JAMA 293 (23): 2284-91. PMID 15956633.
  98. ^ Schachinger V, Erbs S, Elsasser A, Haberbosch W, Hambrecht R, Holschermann H, Yu J, Corti R, Mathey DG, Hamm CW, Suselbeck T, Assmus B, Tonn T, Dimmeler S, Zeiher AM; REPAIR-AMI Investigators (2006). "Intracoronary bone marrow-derived progenitor cells in acute myocardial infarction". N Engl J Med 355 (12): 1210-21. PMID 16990384.
  99. ^ Christman KL, Lee RJ. "Biomaterials for the Treatment of Myocardial Infarction". J Am Coll Cardiol 2006; 48(5): 907-13. PMID 16949479
  100. ^ Nicod P, Gilpin E, Dittrich H, Polikar R, Hjalmarson A, Blacky A, Henning H, Ross J (1989). "Short- and long-term clinical outcome after Q wave and non-Q wave myocardial infarction in a large patient population.". Circulation 79 (3): 528-36. PMID 2645061.
  101. ^ Workers' Compensation FAQ. Prairie View A&M University. Retrieved November 22, 2006.
  102. ^ SIGNIFICANT DECISIONS Subject Index. Board of Industrial Insurance Appeals. Retrieved November 22, 2006.
  103. ^ Compensability Under Workers’ Compensation for Heart Attacks Suffered By Firefighters and Police Officers In the Line of DutyPDF. Department of Labor & Industry, State of Vermont, January 2005.

[edit] External links

Find more information on Myocardial infarction by searching Wikipedia's sister projects:

 Dictionary definitions from Wiktionary
 Textbooks from Wikibooks
 Quotations from Wikiquote
 Source texts from Wikisource
 Images and media from Commons
 News stories from Wikinews
 Learning resources from Wikiversity